SIR/TAC combination more effective in preventing GVHD after allogeneic blood cell transplantation
01:07 EDT 27 Jun 2012 | The Medical News
Researchers at Moffitt Cancer Center have conducted a clinical trial aimed at preventing graft vs. host disease (GVHD) in patients who have received hematopoietic (blood) cell transplants (HCT). The study, comparing the drug tacrolimus (TAC) in combi..
Original Article: SIR/TAC combination more effective in preventing GVHD after allogeneic blood cell transplantation
More From BioPortfolio on "SIR/TAC combination more effective in preventing GVHD after allogeneic blood cell transplantation"
Biotech & Healthcare Channels
World News
Life Science Events
Corporate Database
Market Reports
Categories
Search BioPortfolio:
